Refine
Has Fulltext
- yes (10)
Is part of the Bibliography
- yes (10)
Document Type
- Journal article (9)
- Doctoral Thesis (1)
Language
- English (10)
Keywords
- molecular docking (3)
- molecular dynamics (2)
- Axl tyrosine kinase (1)
- DNA storage (1)
- Einfluss (1)
- Evaluation (1)
- Gene expression vectors (1)
- HIV (1)
- HIV-1 (1)
- Kohlenstoff (1)
- Nanoröhre (1)
- Polymerase chain reaction (1)
- Prognose (1)
- Proteasen (1)
- Proteine (1)
- Retroviren (1)
- Sanger sequencing (1)
- Shotgun method (1)
- Spumaviren (1)
- Synthetic biology (1)
- Virtual sequencing (1)
- Zika virus (1)
- alzheimer's disease (1)
- anti-cancer drug-like molecules (1)
- approved drugs (1)
- chemical similarity (1)
- differentially expressed genes (1)
- diversity (1)
- drug repurposing (1)
- encephalitis dementia (1)
- free energy (1)
- gene ontology (1)
- human immunodeficiency virus (1)
- integrase (1)
- light-gated proteins (1)
- microarray (1)
- molecular modeling (1)
- molecular modelling (1)
- nanobiocomposites (1)
- nanocellulose (1)
- naturally occurring polymorphisms (1)
- pharmacology (1)
- protease; Indinavir; lead expansion; docking; pharmacophore (1)
- protein chip (1)
- protein-protein interaction network (1)
- proteins (1)
- rational drug design (1)
- retroviral proteins (1)
- scaffold search (1)
- simulation (1)
- single-electron transistors (1)
- structure-activity relationship (1)
- virale Proteine (1)
- viruses (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (10) (remove)
Sonstige beteiligte Institutionen
Indinavir (Crivaxan®) is a potent inhibitor of the HIV (human immunodeficiency virus) protease. This enzyme has an important role in viral replication and is considered to be very attractive target for new antiretroviral drugs. However, it becomes less effective due to highly resistant new viral strains of HIV, which have multiple mutations in their proteases. For this reason, we used a lead expansion method to create a new set of compounds with a new mode of action to protease binding site. 1300 compounds chemically diverse from the initial hit were generated and screened to determine their ability to interact with protease and establish their QSAR properties. Further computational analyses revealed one unique compound with different protease binding ability from the initial hit and its role for possible new class of protease inhibitors is discussed in this report.